Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame
Primary	BSA and age-adjusted aortic root diameter (sinuses of Valsalva)	every 12 months
Secondary	The pharmacokinetics of the two drugs by age and dosages	every 12 months
Secondary	Comparative evaluation of the serum levels of total and active TGFb	every 12 months
Secondary	Quantitative assessment of the expression of the mutated gene (FBN1, both 5' and 3')	every 12 months
Secondary	Pharmacogenetic bases of drug responsiveness (Losartan: CYP2C9 gene) (Nebivolol: CYP2D6 gene)	every 12 months
Secondary	Aortic valve regurgitation severity	every 12 months
Secondary	Left ventricular end-diastolic diameter	every 12 months
Secondary	Left ventricular ejection fraction	every 12 months
Secondary	Spirometric lung volumes and flows	every 12 months
Secondary	QoL evaluation basing on SF-36 questionnaire	every 12 months
Secondary	Arterial stiffness (carotids)	every 12 months

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00683124/registered